Diagnosis and Management of Rheumatoid Arthritis: A Review

JAMA - Journal of the American Medical Association

Volumn 320, Issue 13, 2018, Pages 1360-1372

  Aletaha, Daniel ^a   Smolen, Josef S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; GLUCOCORTICOID; METHOTREXATE;

ALGORITHM; COMBINATION DRUG THERAPY; HUMAN; PATHOPHYSIOLOGY; RADIOGRAPHY; RHEUMATOID ARTHRITIS; RISK FACTOR;

ALGORITHMS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; METHOTREXATE; RADIOGRAPHY; RISK FACTORS;

EID: 85054381593     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2018.13103     Document Type: Review

References (108)

1. Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising? results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum. 2010; 62 (6): 1576-1582. doi: 10.1002/art.27425 20191579
2. Aletaha D, Funovits J, Smolen JS. Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction. Ann Rheum Dis. 2011; 70 (5): 733-739. doi: 10.1136/ard.2010.138693 21321002
3. Nam JL, Takase-Minegishi K, Ramiro S, Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2017; 76 (6): 1113-1136. doi: 10.1136/annrheumdis-2016-210713 28283512
4. Chatzidionysiou K, Emamikia S, Nam J, Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2017; 76 (6): 1102-1107. doi: 10.1136/annrheumdis-2016-210711 28356243
5. Ramiro S, Sepriano A, Chatzidionysiou K, Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017; 76 (6): 1101-1136. doi: 10.1136/annrheumdis-2016-210708 28298374
6. Wallach D. The cybernetics of TNF: old views and newer ones. Semin Cell Dev Biol. 2016; 50: 105-114. doi: 10.1016/j.semcdb.2015.10.014 26474540
7. Redlich K, Smolen JS. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov. 2012; 11 (3): 234-250. doi: 10.1038/nrd3669 22378270
8. Aletaha D, Smolen JS. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. Arthritis Rheum. 2011; 63 (12): 3702-3711. doi: 10.1002/art.30634 21953215
9. Viatte S, Barton A. Genetics of rheumatoid arthritis susceptibility, severity, and treatment response. Semin Immunopathol. 2017; 39 (4): 395-408. doi: 10.1007/s00281-017-0630-4 28555384
10. Scott IC, Seegobin SD, Steer S, Predicting the risk of rheumatoid arthritis and its age of onset through modelling genetic risk variants with smoking. PLoS Genet. 2013; 9 (9): e1003808. doi: 10.1371/journal.pgen.1003808 24068971
11. Scher JU, Ubeda C, Equinda M, Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. Arthritis Rheum. 2012; 64 (10): 3083-3094. doi: 10.1002/art.34539 22576262
12. Scher JU, Ubeda C, Artacho A, Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol. 2015; 67 (1): 128-139. doi: 10.1002/art.38892 25319745
13. Tan EM, Smolen JS. Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor. J Exp Med. 2016; 213 (10): 1937-1950. doi: 10.1084/jem.20160792 27621417
14. Silman AJ, Newman J, MacGregor AJ. Cigarette smoking increases the risk of rheumatoid arthritis: results from a nationwide study of disease-discordant twins. Arthritis Rheum. 1996; 39 (5): 732-735. doi: 10.1002/art.1780390504 8639169
15. Stolt P, Källberg H, Lundberg I, Sjögren B, Klareskog L, Alfredsson L; EIRA Study Group. Silica exposure is associated with increased risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis. 2005; 64 (4): 582-586. doi: 10.1136/ard.2004.022053 15319232
16. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987; 30 (11): 1205-1213. doi: 10.1002/art.1780301102 2446635
17. Raychaudhuri S. Recent advances in the genetics of rheumatoid arthritis. Curr Opin Rheumatol. 2010; 22 (2): 109-118. doi: 10.1097/BOR.0b013e328336474d 20075733
18. Scher JU, Sczesnak A, Longman RS, Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife. 2013; 2: e01202. doi: 10.7554/eLife.01202 24192039
19. Wegner N, Wait R, Sroka A, Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase: implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum. 2010; 62 (9): 2662-2672. doi: 10.1002/art.27552 20506214
20. Manfredo Vieira S, Hiltensperger M, Kumar V, Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science. 2018; 359 (6380): 1156-1161. doi: 10.1126/science.aar7201 29590047
21. Pianta A, Arvikar SL, Strle K, Two rheumatoid arthritis-specific autoantigens correlate microbial immunity with autoimmune responses in joints. J Clin Invest. 2017; 127 (8): 2946-2956. doi: 10.1172/JCI93450 28650341
22. Alam J, Kim YC, Choi Y. Potential role of bacterial infection in autoimmune diseases: a new aspect of molecular mimicry. Immune Netw. 2014; 14 (1): 7-13. doi: 10.4110/in.2014.14.1.7 24605075
23. Harley JB, Chen X, Pujato M, Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. Nat Genet. 2018; 50 (5): 699-707. doi: 10.1038/s41588-018-0102-3 29662164
24. Ospelt C, Gay S, Klein K. Epigenetics in the pathogenesis of RA. Semin Immunopathol. 2017; 39 (4): 409-419. doi: 10.1007/s00281-017-0621-5 28324153
25. Aletaha D, Alasti F, Smolen JS. Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials. Arthritis Res Ther. 2015; 17: 229. doi: 10.1186/s13075-015-0736-9 26307354
26. Sokolove J, Johnson DS, Lahey LJ, Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis. Arthritis Rheumatol. 2014; 66 (4): 813-821. doi: 10.1002/art.38307 24757134
27. Nielen MM, van Schaardenburg D, Reesink HW, Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004; 50 (2): 380-386. doi: 10.1002/art.20018 14872479
28. de Hair MJ, van de Sande MG, Ramwadhdoebe TH, Features of the synovium of individuals at risk of developing rheumatoid arthritis: implications for understanding preclinical rheumatoid arthritis. Arthritis Rheumatol. 2014; 66 (3): 513-522. doi: 10.1002/art.38273 24574210
29. Crowson CS, Rollefstad S, Ikdahl E,; A Trans-Atlantic Cardiovascular Consortium for Rheumatoid Arthritis (ATACC-RA). Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2018; 77 (1): 48-54. doi: 10.1136/annrheumdis-2017-211735 28877868
30. Low AS, Symmons DP, Lunt M,; British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA) and the BSRBR Control Centre Consortium. Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis. 2017; 76 (4): 654-660. doi: 10.1136/annrheumdis-2016-209784 28073800
31. Bongartz T, Nannini C, Medina-Velasquez YF, Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010; 62 (6): 1583-1591. doi: 10.1002/art.27405 20155830
32. Sokka T, Kautiainen H, Möttönen T, Hannonen P. Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol. 1999; 26 (8): 1681-1685. 10451062
33. Wolfe F. The natural history of rheumatoid arthritis. J Rheumatol Suppl. 1996; 44: 13-22. 8833046
34. Matcham F, Scott IC, Rayner L, The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014; 44 (2): 123-130. doi: 10.1016/j.semarthrit.2014.05.001 24973898
35. Radner H, Smolen JS, Aletaha D. Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. Rheumatology (Oxford). 2011; 50 (2): 381-388. doi: 10.1093/rheumatology/keq334 21036875
36. Aletaha D, Strand V, Smolen JS, Ward MM. Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. Ann Rheum Dis. 2008; 67 (2): 238-243. doi: 10.1136/ard.2007.071415 17644550
37. Aletaha D, Neogi T, Silman A, 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010; 69: 1580-1588. doi: 10.1136/ard.2010.138461 20699241
38. Radner H, Neogi T, Smolen JS, Aletaha D. Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2014; 73 (1): 114-123. doi: 10.1136/annrheumdis-2013-203284 23592710
39. Aggarwal R, Ringold S, Khanna D, Distinctions between diagnostic and classification criteria? Arthritis Care Res (Hoboken). 2015; 67 (7): 891-897. doi: 10.1002/acr.22583 25776731
40. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005; 52 (11): 3381-3390. doi: 10.1002/art.21405 16258899
41. Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis. 2002; 61 (4): 290-297. doi: 10.1136/ard.61.4.290 11874828
42. Aletaha D, Nell VPK, Stamm T, Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005; 7 (4): R796-R806. doi: 10.1186/ar1740 15987481
43. van der Heijde DM, van Riel PL, van Leeuwen MA, van 't Hof MA, van Rijswijk MH, van de Putte LB. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis: a prospective follow-up study of 147 patients. Br J Rheumatol. 1992; 31 (8): 519-525. doi: 10.1093/rheumatology/31.8.519 1386548
44. Smolen JS, Van Der Heijde DM, St Clair EW,; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum. 2006; 54 (3): 702-710. doi: 10.1002/art.21678 16508926
45. Smolen JS, Breedveld FC, Burmester GR, Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016; 75 (1): 3-15. doi: 10.1136/annrheumdis-2015-207524 25969430
46. Aletaha D, Alasti F, Smolen JS. Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point. Ann Rheum Dis. 2016; 75 (8): 1479-1485. doi: 10.1136/annrheumdis-2015-208324 26420577
47. Felson DT, Smolen JS, Wells G, American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011; 70 (3): 404-413. doi: 10.1136/ard.2011.149765 21292833
48. Dale J, Stirling A, Zhang R, Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. Ann Rheum Dis. 2016; 75 (6): 1043-1050. doi: 10.1136/annrheumdis-2015-208941 27026689
49. Emery P, Bingham CO III, Burmester GR, Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Ann Rheum Dis. 2017; 76 (1): 96-104. doi: 10.1136/annrheumdis-2015-209057 27165179
50. Breedveld FC, Weisman MH, Kavanaugh AF, The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006; 54 (1): 26-37. doi: 10.1002/art.21519 16385520
51. Smolen JS, Kalden JR, Scott DL,; European Leflunomide Study Group. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet. 1999; 353 (9149): 259-266. doi: 10.1016/S0140-6736(98)09403-3 9929017
52. van Vollenhoven RF, Fleischmann R, Cohen S,; ORAL Standard Investigators. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012; 367 (6): 508-519. doi: 10.1056/NEJMoa1112072 22873531
53. Burmester GR, Blanco R, Charles-Schoeman C,; ORAL Step Investigators. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013; 381 (9865): 451-460. doi: 10.1016/S0140-6736(12)61424-X 23294500
54. Dougados M, van der Heijde D, Chen YC, Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017; 76 (1): 88-95. doi: 10.1136/annrheumdis-2016-210094 27689735
55. Genovese MC, Kremer J, Zamani O, Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016; 374 (13): 1243-1252. doi: 10.1056/NEJMoa1507247 27028914
56. Smolen JS, Kay J, Doyle MK,; GO-AFTER Study Investigators. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009; 374 (9685): 210-221. doi: 10.1016/S0140-6736(09)60506-7 19560810
57. Smolen JS, Beaulieu A, Rubbert-Roth A,; OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008; 371 (9617): 987-997. doi: 10.1016/S0140-6736(08)60453-5 18358926
58. Emery P, Keystone E, Tony HP, IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008; 67 (11): 1516-1523. doi: 10.1136/ard.2008.092932 18625622
59. Emery P, Fleischmann R, Filipowicz-Sosnowska A,; DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006; 54 (5): 1390-1400. doi: 10.1002/art.21778 16649186
60. Cohen SB, Emery P, Greenwald MW,; REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006; 54 (9): 2793-2806. doi: 10.1002/art.22025 16947627
61. Kremer JM, Genant HK, Moreland LW, Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006; 144 (12): 865-876. doi: 10.7326/0003-4819-144-12-200606200-00003 16785475
62. Genovese MC, Becker JC, Schiff M, Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005; 353 (11): 1114-1123. doi: 10.1056/NEJMoa050524 16162882
63. Kay J, Schoels MM, Dörner T,; Task Force on the Use of Biosimilars to Treat Rheumatological Diseases. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018; 77 (2): 165-174. doi: 10.1136/annrheumdis-2017-211937 28866648
64. Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landewé R. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2014; 73 (1): 3-5. doi: 10.1136/annrheumdis-2013-204317 24072562
65. Hoffmeister RT. Methotrexate therapy in rheumatoid arthritis: 15 years experience. Am J Med. 1983; 75 (6A): 69-73. doi: 10.1016/0002-9343(83)90477-1 6660241
66. van Ede AE, Laan RF, Rood MJ, Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2001; 44 (7): 1515-1524. doi: 10.1002/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7 11465701
67. Nam JL, Villeneuve E, Hensor EM, Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis. 2014; 73 (1): 75-85. doi: 10.1136/annrheumdis-2013-203440 23912798
68. van der Heijde DM, van Riel PL, Nuver-Zwart IH, van de Putte LB. Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up. Lancet. 1990; 335 (8688): 539. doi: 10.1016/0140-6736(90)90771-V 1968547
69. Smolen JS, Landewé R, Bijlsma J, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017; 76 (6): 960-977. doi: 10.1136/annrheumdis-2016-210715 28264816
70. Singh JA, Saag KG, Bridges SL Jr,; American College of Rheumatology. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016; 68 (1): 1-25. doi: 10.1002/acr.22783 26545825
71. Vastesaeger N, Xu S, Aletaha D, St Clair EW, Smolen JS. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford). 2009; 48 (9): 1114-1121. doi: 10.1093/rheumatology/kep155 19589891
72. Kiely P, Walsh D, Williams R, Young A; Early Rheumatoid Arthritis Network. Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity-the early RA network (ERAN). Rheumatology (Oxford). 2011; 50 (5): 926-931. doi: 10.1093/rheumatology/keq406 21169343
73. Smolen JS, Burmester GR, Combe B, Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet. 2016; 388 (10061): 2763-2774. doi: 10.1016/S0140-6736(16)31651-8 27863807
74. Burmester GR, Rigby WF, van Vollenhoven RF, Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis. 2016; 75 (6): 1081-1091. doi: 10.1136/annrheumdis-2015-207628 26511996
75. Emery P, Burmester GR, Bykerk VP, Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015; 74 (1): 19-26. doi: 10.1136/annrheumdis-2014-206106 25367713
76. Kaneko Y, Atsumi T, Tanaka Y, Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). Ann Rheum Dis. 2016; 75 (11): 1917-1923. doi: 10.1136/annrheumdis-2015-208426 26733110
77. Fleischmann R, Mysler E, Hall S,; ORAL Strategy Investigators. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017; 390 (10093): 457-468. doi: 10.1016/S0140-6736(17)31618-5 28629665
78. Gabay C, Emery P, van Vollenhoven R,; ADACTA Study Investigators. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial [published correction appears in Lancet. 2013;381(9877):1540]. Lancet. 2013; 381 (9877): 1541-1550. doi: 10.1016/S0140-6736(13)60250-0 23515142
79. Burmester GR, Lin Y, Patel R, Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2017; 76 (5): 840-847. doi: 10.1136/annrheumdis-2016-210310 27856432
80. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016; 388 (10055): 2023-2038. doi: 10.1016/S0140-6736(16)30173-8 27156434
81. Taylor PC, Keystone EC, van der Heijde D, Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017; 376 (7): 652-662. doi: 10.1056/NEJMoa1608345 28199814
82. Genovese MC, Fleischmann R, Combe B, Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018; 391 (10139): 2513-2524. doi: 10.1016/S0140-6736(18)31116-4 29908670
83. Burmester GR, Kremer JM, Van den Bosch F, Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018; 391 (10139): 2503-2512. doi: 10.1016/S0140-6736(18)31115-2 29908669
84. Smolen JS, Cohen S, Emery P, Upadacitinib as monotherapy: a phase 3 randomised controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate [abstract]. Ann Rheum Dis. 2018; 77 (suppl): A67.
85. Westhovens R, Taylor PC, Alten R, Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis. 2017; 76 (6): 998-1008. doi: 10.1136/annrheumdis-2016-210104 27993829
86. Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol. 2015; 11 (5): 276-289. doi: 10.1038/nrrheum.2015.8 25687177
87. Ducreux J, Durez P, Galant C, Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014; 66 (1): 15-23. doi: 10.1002/art.38202 24449571
88. Smolen JS, Han C, Bala M,; ATTRACT Study Group. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 2005; 52 (4): 1020-1030. doi: 10.1002/art.20982 15818697
89. Smolen JS, Avila JC, Aletaha D. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis. 2012; 71 (5): 687-693. doi: 10.1136/annrheumdis-2011-200395 22121130
90. Binder NB, Puchner A, Niederreiter B, Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis. Arthritis Rheum. 2013; 65 (3): 608-617. doi: 10.1002/art.37797 23280418
91. Smolen JS, Szumski A, Koenig AS, Jones TV, Marshall L. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial. Arthritis Res Ther. 2018; 20 (1): 8. doi: 10.1186/s13075-017-1484-9 29338762
92. Smolen JS, Nash P, Durez P, Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet. 2013; 381 (9870): 918-929. doi: 10.1016/S0140-6736(12)61811-X 23332236
93. Tanaka Y, Hirata S, Kubo S, Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis. 2015; 74 (2): 389-395. doi: 10.1136/annrheumdis-2013-204016 24288014
94. Rutherford AI, Patarata E, Subesinghe S, Hyrich KL, Galloway JB. Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford). 2018; 57 (6): 997-1001. doi: 10.1093/rheumatology/key023 29529307
95. Smolen JS, Agarwal SK, Ilivanova E, A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate. Ann Rheum Dis. 2017; 76 (5): 831-839. doi: 10.1136/annrheumdis-2016-209831 28087506
96. van der Lubbe PA, Dijkmans BA, Markusse HM, Nässander U, Breedveld FC. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum. 1995; 38 (8): 1097-1106. doi: 10.1002/art.1780380812 7639806
97. Genovese MC, Durez P, Richards HB, Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis. 2013; 72 (6): 863-869. doi: 10.1136/annrheumdis-2012-201601 22730366
98. Genovese MC, Cohen SB, Wofsy D, A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol. 2011; 38 (5): 846-854. doi: 10.3899/jrheum.100602 21285160
99. National Assembly (Parliament). Bundesgesetz, mit dem das Allgemeine Sozialversicherungsgesetz geändert wird (Amendment of the Social Security Law). https://www.parlament.gv.at/PAKT/VHG/XXV/BNR/BNR-00472/fnameorig-626979.html. 2018. Accessed August 30, 2018.
100. Aga AB, Lie E, Uhlig T, Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010. Ann Rheum Dis. 2015; 74 (2): 381-388. doi: 10.1136/annrheumdis-2013-204020 24285493
101. Listing J, Kekow J, Manger B, Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis. 2015; 74 (2): 415-421. doi: 10.1136/annrheumdis-2013-204021 24291654
102. Putrik P, Ramiro S, Kvien TK,; Working Group "Equity in Access to Treatment of Rheumatoid Arthritis in Europe." Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014; 73 (1): 198-206. doi: 10.1136/annrheumdis-2012-202603 23467636
103. Cheung TT, McInnes IB. Future therapeutic targets in rheumatoid arthritis? Semin Immunopathol. 2017; 39 (4): 487-500. doi: 10.1007/s00281-017-0623-3 28451787
104. Burmester GR, McInnes IB, Kremer JM, Mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor α monoclonal antibody: long-term safety and efficacy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2018; 70 (5): 679-689. doi: 10.1002/art.40420 29361199
105. Blüml S, Sahin E, Saferding V, Phosphatase and tensin homolog (PTEN) in antigen-presenting cells controls Th17-mediated autoimmune arthritis. Arthritis Res Ther. 2015; 17: 230. doi: 10.1186/s13075-015-0742-y 26307404
106. Winthrop KL, Strand V, van der Heijde D, The unmet need in rheumatology: reports from the targeted therapies meeting 2017. Clin Immunol. 2018; 186: 87-93. doi: 10.1016/j.clim.2017.08.009 28811201
107. Gerlag DM, Raza K, van Baarsen LG, EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis. 2012; 71 (5): 638-641. doi: 10.1136/annrheumdis-2011-200990 22387728
108. Deane KD, Striebich CC, Holers VM. Prevention of rheumatoid arthritis: now is the time, but how to proceed? Arthritis Rheumatol. 2017; 69 (5): 873-877. doi: 10.1002/art.40061 28217918